Tactile Systems Technology Reports Strong Q4 and Full-Year 2025 Results

Company sees double-digit revenue growth, improved profitability, and outlines 2026 outlook amid new Medicare prior authorization requirement

Published on Feb. 20, 2026

Got story updates? Submit your updates here. ›

Tactile Systems Technology (NASDAQ:TCMD) reported double-digit revenue growth and improved profitability for the fourth quarter and full year 2025, driven by continued momentum in its lymphedema franchise and a sharp increase in airway clearance revenue. Management also outlined its 2026 outlook, which incorporates potential short-term disruption from a new Medicare prior authorization requirement for pneumatic compression devices, and discussed the company's acquisition of LymphaTech.

Why it matters

Tactile Systems Technology's strong financial performance and strategic initiatives, including the LymphaTech acquisition, demonstrate the company's ability to capitalize on growing demand for its lymphedema and airway clearance products. However, the new Medicare prior authorization requirement could pose a temporary challenge as the industry adjusts, underscoring the importance of Tactile's investments in documentation workflows and payer engagement.

The details

In the fourth quarter, Tactile Systems reported a 21% year-over-year increase in revenue to $103.6 million, with the lymphedema business growing 16% and airway clearance revenue surging 66%. For the full year 2025, total revenue was $329.5 million, up 12% year-over-year, and the company expanded gross margin by 190 basis points to 75.9%. Tactile also generated strong cash flow, allowing it to repay debt and repurchase shares. Management attributed the results to successful execution of its commercial strategy, including investments in sales capacity and technology-enabled workflows. The company also announced the acquisition of LymphaTech, which provides digital measurement and monitoring capabilities to support Tactile's evolution into a 'comprehensive integrated lymphedema solutions leader.'

  • Tactile Systems reported fourth quarter and full year 2025 results on February 18, 2026.
  • CMS announced in January 2026 that suppliers will need prior authorization for basic and advanced pneumatic compression device codes billed under traditional Medicare fee-for-service starting April 13, 2026.

The players

Tactile Systems Technology

A medical device company specializing in the design, manufacture and marketing of home-use pneumatic compression therapy systems for the treatment of lymphedema and other chronic edema-related conditions.

LymphaTech

A privately held company focused on assessing and monitoring fluid in patients with chronic swelling, using proprietary algorithms and mobile scanning to generate clinical-grade 3D models and provide fluid volume and circumference measurements.

Sheri Dodd

Chief Executive Officer of Tactile Systems Technology.

Elaine Birkemeyer

Chief Financial Officer of Tactile Systems Technology.

Got photos? Submit your photos here. ›

What they’re saying

“2025 was 'a pivotal year' as the company invested in commercial and operational initiatives while delivering 'strong, profitable revenue growth.'”

— Sheri Dodd, Chief Executive Officer (Tactile Systems Technology earnings call)

“Demand has benefited from growing awareness of bronchiectasis and available treatment options, and she noted that the company believes it has achieved a market-leading position in the category, supported by 'prioritized placement agreements' within the top 10 respiratory durable medical equipment (DME) providers.”

— Sheri Dodd, Chief Executive Officer (Tactile Systems Technology earnings call)

“Prior authorization will add administrative steps and could temporarily affect the broader lymphedema market as the industry adjusts, but she said the company does not expect it to change its ability to grow in line with the overall market during the transition.”

— Elaine Birkemeyer, Chief Financial Officer (Tactile Systems Technology earnings call)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Tactile Systems Technology's strong financial performance, strategic initiatives, and investments in commercial and operational capabilities position the company well to navigate the new Medicare prior authorization requirement and continue driving growth in its lymphedema and airway clearance franchises. The acquisition of LymphaTech also supports the company's evolution into a comprehensive integrated lymphedema solutions provider.